<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The aim of this study was to determine whether treatment for Helicobacter pylori (H. pylori) for patients with <z:e sem="disease" ids="C0013395" disease_type="Disease or Syndrome" abbrv="">dyspepsia</z:e> or a history of <z:hpo ids='HP_0004398'>peptic ulcer</z:hpo> decreases hospital expenditures </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Patients receiving acid suppressive medications were interviewed </plain></SENT>
<SENT sid="2" pm="."><plain>Those with a documented <z:mpath ids='MPATH_579'>ulcer</z:mpath>, a self-reported <z:mpath ids='MPATH_579'>ulcer</z:mpath>, or <z:e sem="disease" ids="C0013395" disease_type="Disease or Syndrome" abbrv="">dyspepsia</z:e> were tested for H. pylori and treated with antibiotics if seropositive </plain></SENT>
<SENT sid="3" pm="."><plain>Acid suppressive medications were stopped on completion of H. pylori therapy unless there was a history of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) or <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and were started again at the discretion of primary care providers </plain></SENT>
<SENT sid="4" pm="."><plain>Total hospital costs and GI medication costs in the 12 months before H. pylori treatment were compared to costs 12 months after H. pylori treatment </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 432 consecutive patients were treated for H. pylori </plain></SENT>
<SENT sid="6" pm="."><plain>Of the patients, 125 (29%) had <z:e sem="disease" ids="C0013395" disease_type="Disease or Syndrome" abbrv="">dyspepsia</z:e>, 45 (10%) documented <z:hpo ids='HP_0004398'>peptic ulcer</z:hpo>, and 262 (61%) self-reported <z:hpo ids='HP_0004398'>peptic ulcer</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Total costs (mean 327 US dollars +/- 349 vs 291 USA dollars +/- 362, p = 0.06) and medication costs (mean 207 US dollars +/- 237 vs 224 US dollars +/- 277, p = 0.38) were not significantly different after treatment versus before treatment </plain></SENT>
<SENT sid="8" pm="."><plain>A significant decrease in expenditures was limited to patients chronically on acid suppressive medications who had documented <z:hpo ids='HP_0004398'>peptic ulcers</z:hpo> and no history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> or <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (mean 482 US dollars +/- 274 vs 282 US dollars +/- 218, p = 0.03) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Treatment of H. pylori for patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0013395" disease_type="Disease or Syndrome" abbrv="">dyspepsia</z:e> or self-reported <z:hpo ids='HP_0004398'>peptic ulcer</z:hpo> does not reduce expenditures over 1 yr of follow up </plain></SENT>
<SENT sid="10" pm="."><plain>H. pylori treatment for patients chronically receiving acid suppressive treatment with a prior documented <z:mpath ids='MPATH_579'>ulcer</z:mpath> significantly reduces expenditures if <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> are absent </plain></SENT>
</text></document>